

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**The United Laboratories International Holdings Limited**  
**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 3933)

**PROPOSED AMENDMENTS TO THE ARTICLES OF  
ASSOCIATION AND ADOPTION OF THE AMENDED AND  
RESTATED ARTICLES OF ASSOCIATION**

This announcement is made by The United Laboratories International Holdings Limited (the “**Company**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) in relation to the proposed amendments to the existing articles of association of Company (the “**Existing Articles**”) and adoption of the amended and restated articles of association of Company (the “**Amended and Restated Articles**”).

Pursuant to the Consultation Conclusions on Listing Regime for Overseas Issuers published by The Stock Exchange of Hong Kong Limited in November 2021, the Listing Rules have been amended with effect from 1 January 2022 which requires, among others, listed issuers to adopt a uniform set of 14 “Core Standards” for shareholder protections for issuers. As such, the board of directors of the Company (the “**Board**”) proposes to amend the Existing Articles for the purposes of, among others, (i) bringing the Existing Articles in line with amendments made to Appendix III to the Listing Rules and applicable laws of the Cayman Islands; (ii) providing flexibility to the Company in relation to conduct of general meetings; and (iii) making other consequential and housekeeping changes (collectively, the “**Proposed Amendments**”) and to adopt the Amended and Restated Articles in substitution for, and to the exclusion of, the Existing Articles.

The Proposed Amendments and the proposed adoption of the Amended and Restated Articles shall be subject to the passing of a special resolution by the shareholders of the Company at the forthcoming extraordinary general meeting of the Company (the “EGM”). A circular containing, among others, details of the Proposed Amendments and a notice convening the EGM will be despatched to the Company’s shareholders as soon as practicable.

By Order of the Board  
**The United Laboratories International Holdings Limited**  
**Tsoi Hoi Shan**  
*Chairman*

Hong Kong, 13 September 2023

*As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.*